French ccAFU guidelines - update 2020-2022 : prostate cancer
Copyright © 2020 Elsevier Masson SAS. All rights reserved..
OBJECTIVE: - The purpose of the guidelines national committee ccAFU was to propose updated french guidelines for prostate cancer.
METHODS: - A Medline search was achieved between 2018 and 2020, as regards diagnosis, options of treatment and follow-up of prostate cancer (PCA), and to evaluate the different references specifying their levels of evidence.
RESULTS: - The guidelines outline the genetics, epidemiology and diagnosis of prostate cancer, as well as the concepts of screening and early detection. MRI, the gold standard imaging test for localized cancer, is indicated before prostate biopsies are performed. The therapeutic methods are detailed and indicated according to the clinical situation. Active surveillance is a reference therapeutic option for low-risk tumours with a low evolutionary risk. Early salvage radiotherapy is indicated in case of biological recurrence after radical prostatectomy. Androgen deprivation therapy (ADT) remains the backbone therapy in the metastatic stage. Docetaxel in combination with ADT improves overall first-line survival in synchronous metastatic prostate cancer. In this situation, the combination of ADT with abiraterone is also a standard of care regardless of tumor volume. Recent data indicate that ADT should be indicated with a new generation of hormone therapy (Apalutamide or Enzalutamide) in metastatic synchronous or metachronous patients, regardless of tumour volume. Local treatment of prostate cancer with radiotherapy improves survival in synchronous oligometastatic patients. Targeted treatment of metastases is being evaluated. In patients with castration-resistant prostate cancer (CRPC), new therapies that have emerged in recent years help to better control tumor progression and improve survival.
CONCLUSION: - These updated french guidelines will contribute to increase the level of urological care for the diagnosis and treatment for prostate cancer.
| Errataetall: |
ErratumIn: Prog Urol. 2021 May;31(6):381-382. - PMID 33941457 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie - 30(2020), 12S vom: 22. Nov., Seite S136-S251 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Recommandations françaises du Comité de cancérologie de l’AFU – actualisation 2020–2022 : cancer de la prostate |
|---|
| Beteiligte Personen: |
Rozet, F [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.06.2021 Date Revised 24.06.2021 published: Print ErratumIn: Prog Urol. 2021 May;31(6):381-382. - PMID 33941457 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S1166-7087(20)30752-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319140466 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319140466 | ||
| 003 | DE-627 | ||
| 005 | 20231225170823.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/S1166-7087(20)30752-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1063.xml |
| 035 | |a (DE-627)NLM319140466 | ||
| 035 | |a (NLM)33349424 | ||
| 035 | |a (PII)S1166-7087(20)30752-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Rozet, F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a French ccAFU guidelines - update 2020-2022 |b prostate cancer |
| 246 | 3 | 3 | |a Recommandations françaises du Comité de cancérologie de l’AFU – actualisation 2020–2022 : cancer de la prostate |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.06.2021 | ||
| 500 | |a Date Revised 24.06.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumIn: Prog Urol. 2021 May;31(6):381-382. - PMID 33941457 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a OBJECTIVE: - The purpose of the guidelines national committee ccAFU was to propose updated french guidelines for prostate cancer | ||
| 520 | |a METHODS: - A Medline search was achieved between 2018 and 2020, as regards diagnosis, options of treatment and follow-up of prostate cancer (PCA), and to evaluate the different references specifying their levels of evidence | ||
| 520 | |a RESULTS: - The guidelines outline the genetics, epidemiology and diagnosis of prostate cancer, as well as the concepts of screening and early detection. MRI, the gold standard imaging test for localized cancer, is indicated before prostate biopsies are performed. The therapeutic methods are detailed and indicated according to the clinical situation. Active surveillance is a reference therapeutic option for low-risk tumours with a low evolutionary risk. Early salvage radiotherapy is indicated in case of biological recurrence after radical prostatectomy. Androgen deprivation therapy (ADT) remains the backbone therapy in the metastatic stage. Docetaxel in combination with ADT improves overall first-line survival in synchronous metastatic prostate cancer. In this situation, the combination of ADT with abiraterone is also a standard of care regardless of tumor volume. Recent data indicate that ADT should be indicated with a new generation of hormone therapy (Apalutamide or Enzalutamide) in metastatic synchronous or metachronous patients, regardless of tumour volume. Local treatment of prostate cancer with radiotherapy improves survival in synchronous oligometastatic patients. Targeted treatment of metastases is being evaluated. In patients with castration-resistant prostate cancer (CRPC), new therapies that have emerged in recent years help to better control tumor progression and improve survival | ||
| 520 | |a CONCLUSION: - These updated french guidelines will contribute to increase the level of urological care for the diagnosis and treatment for prostate cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Cancer de la prostate | |
| 650 | 4 | |a Diagnosis | |
| 650 | 4 | |a Diagnostic | |
| 650 | 4 | |a Guidelines | |
| 650 | 4 | |a Medical Subject Headings (MeSH) | |
| 650 | 4 | |a Medical Subject Headings (MeSH) Prostate cancer | |
| 650 | 4 | |a Recommandations | |
| 650 | 4 | |a Traitement | |
| 650 | 4 | |a Treatment | |
| 700 | 1 | |a Mongiat-Artus, P |e verfasserin |4 aut | |
| 700 | 1 | |a Hennequin, C |e verfasserin |4 aut | |
| 700 | 1 | |a Beauval, J B |e verfasserin |4 aut | |
| 700 | 1 | |a Beuzeboc, P |e verfasserin |4 aut | |
| 700 | 1 | |a Cormier, L |e verfasserin |4 aut | |
| 700 | 1 | |a Fromont-Hankard, G |e verfasserin |4 aut | |
| 700 | 1 | |a Mathieu, R |e verfasserin |4 aut | |
| 700 | 1 | |a Ploussard, G |e verfasserin |4 aut | |
| 700 | 1 | |a Renard-Penna, R |e verfasserin |4 aut | |
| 700 | 1 | |a Brenot-Rossi, I |e verfasserin |4 aut | |
| 700 | 1 | |a Bruyere, F |e verfasserin |4 aut | |
| 700 | 1 | |a Cochet, A |e verfasserin |4 aut | |
| 700 | 1 | |a Crehange, G |e verfasserin |4 aut | |
| 700 | 1 | |a Cussenot, O |e verfasserin |4 aut | |
| 700 | 1 | |a Lebret, T |e verfasserin |4 aut | |
| 700 | 1 | |a Rebillard, X |e verfasserin |4 aut | |
| 700 | 1 | |a Soulié, M |e verfasserin |4 aut | |
| 700 | 1 | |a Brureau, L |e verfasserin |4 aut | |
| 700 | 1 | |a Méjean, A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie |d 1997 |g 30(2020), 12S vom: 22. Nov., Seite S136-S251 |w (DE-627)NLM012649481 |x 1166-7087 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2020 |g number:12S |g day:22 |g month:11 |g pages:S136-S251 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S1166-7087(20)30752-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2020 |e 12S |b 22 |c 11 |h S136-S251 | ||